Demant T, Bedford D, Packard C J, Shepherd J
Institute of Clinical Biochemistry, Glasgow Royal Infirmary, Scotland.
J Clin Invest. 1991 Nov;88(5):1490-501. doi: 10.1172/JCI115459.
This study examined apolipoprotein (apo) B metabolism in normolipemic subjects homozygous for the apo E2 (n = 4), apo E3 (n = 5), or apo E4 (n = 5) phenotype. Radioiodinated very low density lipoprotein (VLDL1) (ultracentrifuge flotation rate [Sf] 60-400) and VLDL2 (Sf 20-60) were injected into volunteers and the conversion of apo B was followed through intermediate density lipoprotein (IDL) to low density lipoprotein (LDL). Subjects homozygous for E3 converted approximately 50% of LVDL2 to LDL, the remainder being lost by direct catabolism. Those with the E2 phenotype produced less VLDL1, but converted more of it to VLDL2 (compared to E3 subjects). They displayed a characteristic dyslipidemia with the presence of slowly catabolized VLDL1 and VLDL2 remnants. LDL levels were low owing to increased direct catabolism of VLDL2 and IDL and a reduced efficiency of delipidation; only 25% of VLDL2 apo B was directed to LDL production. In contrast, E4 subjects converted more VLDL2 apo B to LDL than E3 subjects. About 70% of VLDL2 apo B was found in LDL; direct catabolism of VLDL and IDL was reduced as was the fractional catabolic rate of LDL (0.2 vs. 0.26 in E3 subjects). These changes in the VLDL----IDL----LDL metabolic cascade can in part be explained by alterations in hepatic LDL receptors with E2 subjects having higher and E4 subjects lower activities than those in E3 homozygotes.
本研究检测了载脂蛋白E2(n = 4)、载脂蛋白E3(n = 5)或载脂蛋白E4(n = 5)表型的血脂正常受试者的载脂蛋白(apo)B代谢情况。将放射性碘标记的极低密度脂蛋白(VLDL1)(超速离心漂浮率[Sf] 60 - 400)和VLDL2(Sf 20 - 60)注入志愿者体内,并追踪apo B从中间密度脂蛋白(IDL)到低密度脂蛋白(LDL)的转化过程。E3纯合子受试者将约50%的VLDL2转化为LDL,其余部分通过直接分解代谢而消失。具有E2表型的受试者产生的VLDL1较少,但将更多的VLDL1转化为VLDL2(与E3受试者相比)。他们表现出一种特征性的血脂异常,存在分解代谢缓慢的VLDL1和VLDL2残粒。由于VLDL2和IDL的直接分解代谢增加以及脂质清除效率降低,LDL水平较低;只有25%的VLDL2 apo B用于LDL的生成。相比之下,E4受试者比E3受试者将更多的VLDL2 apo B转化为LDL。在LDL中发现约70%的VLDL2 apo B;VLDL和IDL的直接分解代谢减少,LDL的分解代谢率也降低(E3受试者为0.26,E4受试者为0.2)。VLDL→IDL→LDL代谢级联反应中的这些变化部分可由肝脏LDL受体的改变来解释,E2受试者的受体活性高于E3纯合子受试者,而E4受试者的受体活性低于E3纯合子受试者。